Circulating Tumor Cells: From Basic to Translational Research

Overview

Journal Clin Chem

Publisher Oxford University Press

Specialty Biochemistry

Date 2024 Jan 4

PMID 38175586

Authors

Luis Enrique Cortes-Hernandez

Zahra Eslami-S

Klaus Pantel

Catherine Alix-Panabieres

Affiliations

Soon will be listed here.

Abstract

Background: Metastasis is the leading cause of cancer-related deaths. Most studies have focused on the primary tumor or on overt metastatic lesions, leaving a significant knowledge gap concerning blood-borne cancer cell dissemination, a major step in the metastatic cascade. Circulating tumor cells (CTCs) in the blood of patients with solid cancer can now be enumerated and investigated at the molecular level, giving unexpected information on the biology of the metastatic cascade.

Content: Here, we reviewed recent advances in basic and translational/clinical research on CTCs as key elements in the metastatic cascade.

Summary: Findings from translational studies on CTCs have elucidated the complexity of the metastatic process. Fully understanding this process will open new potential avenues for cancer therapeutic and diagnostic strategies to propose precision medicine to all cancer patients.

Citing Articles

Unlocking the promise of liquid biopsies in precision oncology.

Pando-Caciano A, Trivedi R, Pauwels J, Nowakowska J, Cavina B, Falkman L J Liq Biopsy. 2025; 3:100151.

PMID: 40026562 PMC: 11863887. DOI: 10.1016/j.jlb.2024.100151.

Proteomic and transcriptomic analyses identify apo-transcobalamin-II as a biomarker of overall survival in osteosarcoma.

Lacinski R, Dziadowicz S, Roth C, Ma L, Melemai V, Fitzpatrick B Front Oncol. 2024; 14:1417459.

PMID: 39493449 PMC: 11527601. DOI: 10.3389/fonc.2024.1417459.

Liquid biopsy: paving a new avenue for cancer research.

Kurma K, Eslami-S Z, Alix-Panabieres C, Cayrefourcq L Cell Adh Migr. 2024; 18(1):1-26.

PMID: 39219215 PMC: 11370957. DOI: 10.1080/19336918.2024.2395807.

Improving platelet-RNA-based diagnostics: a comparative analysis of machine learning models for cancer detection and multiclass classification.

Jopek M, Pastuszak K, Sieczczynski M, Cygert S, Zaczek A, Rondina M Mol Oncol. 2024; 18(11):2743-2754.

PMID: 38887841 PMC: 11547247. DOI: 10.1002/1878-0261.13689.

References

Zapatero A, Gomez-Caamano A, Cabeza Rodriguez M, Muinelo-Romay L, de Vidales C, Abalo A . Detection and dynamics of circulating tumor cells in patients with high-risk prostate cancer treated with radiotherapy and hormones: a prospective phase II study. Radiat Oncol. 2020; 15(1):137. PMC: 7268302. DOI: 10.1186/s13014-020-01577-5. View

Riethdorf S, OFlaherty L, Hille C, Pantel K . Clinical applications of the CellSearch platform in cancer patients. Adv Drug Deliv Rev. 2018; 125:102-121. DOI: 10.1016/j.addr.2018.01.011. View

van Dalum G, Stam G, Scholten L, Mastboom W, Vermes I, Tibbe A . Importance of circulating tumor cells in newly diagnosed colorectal cancer. Int J Oncol. 2015; 46(3):1361-8. DOI: 10.3892/ijo.2015.2824. View

Bidard F, Jacot W, Kiavue N, Dureau S, Kadi A, Brain E . Efficacy of Circulating Tumor Cell Count-Driven vs Clinician-Driven First-line Therapy Choice in Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer: The STIC CTC Randomized Clinical Trial. JAMA Oncol. 2020; 7(1):34-41. PMC: 7645742. DOI: 10.1001/jamaoncol.2020.5660. View

Bergmann S, Coym A, Ott L, Soave A, Rink M, Janning M . Evaluation of PD-L1 expression on circulating tumor cells (CTCs) in patients with advanced urothelial carcinoma (UC). Oncoimmunology. 2020; 9(1):1738798. PMC: 7199812. DOI: 10.1080/2162402X.2020.1738798. View

Bidard F, Peeters D, Fehm T, Nole F, Gisbert-Criado R, Mavroudis D . Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data. Lancet Oncol. 2014; 15(4):406-14. DOI: 10.1016/S1470-2045(14)70069-5. View

Yang J, Antin P, Berx G, Blanpain C, Brabletz T, Bronner M . Guidelines and definitions for research on epithelial-mesenchymal transition. Nat Rev Mol Cell Biol. 2020; 21(6):341-352. PMC: 7250738. DOI: 10.1038/s41580-020-0237-9. View

Lorente D, Olmos D, Mateo J, Dolling D, Bianchini D, Seed G . Circulating tumour cell increase as a biomarker of disease progression in metastatic castration-resistant prostate cancer patients with low baseline CTC counts. Ann Oncol. 2018; 29(7):1554-1560. DOI: 10.1093/annonc/mdy172. View

Yang G, Xie J, Zhang S, Gu W, Yuan J, Wang R . Clinical Significance of Mesenchymal Circulating Tumor Cells in Patients With Oligometastatic Hormone-Sensitive Prostate Cancer Who Underwent Cytoreductive Radical Prostatectomy. Front Oncol. 2022; 11:812549. PMC: 8810514. DOI: 10.3389/fonc.2021.812549. View

10.

Aceto N, Bardia A, Miyamoto D, Donaldson M, Wittner B, Spencer J . Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis. Cell. 2014; 158(5):1110-1122. PMC: 4149753. DOI: 10.1016/j.cell.2014.07.013. View

11.

de Bono J, Scher H, Montgomery R, Parker C, Miller M, Tissing H . Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res. 2008; 14(19):6302-9. DOI: 10.1158/1078-0432.CCR-08-0872. View

12.

Cortes-Hernandez L, Eslami-S Z, Dujon A, Giraudeau M, Ujvari B, Thomas F . Do malignant cells sleep at night?. Genome Biol. 2020; 21(1):276. PMC: 7659113. DOI: 10.1186/s13059-020-02179-w. View

13.

Cayrefourcq L, Thomas F, Mazard T, Assenat E, Assou S, Alix-Panabieres C . Selective treatment pressure in colon cancer drives the molecular profile of resistant circulating tumor cell clones. Mol Cancer. 2021; 20(1):30. PMC: 7869222. DOI: 10.1186/s12943-021-01326-6. View

14.

Follain G, Osmani N, Azevedo A, Allio G, Mercier L, Karreman M . Hemodynamic Forces Tune the Arrest, Adhesion, and Extravasation of Circulating Tumor Cells. Dev Cell. 2018; 45(1):33-52.e12. DOI: 10.1016/j.devcel.2018.02.015. View

15.

Lambert A, Pattabiraman D, Weinberg R . Emerging Biological Principles of Metastasis. Cell. 2017; 168(4):670-691. PMC: 5308465. DOI: 10.1016/j.cell.2016.11.037. View

16.

Stergiopoulou D, Markou A, Strati A, Zavridou M, Tzanikou E, Mastoraki S . Comprehensive liquid biopsy analysis as a tool for the early detection of minimal residual disease in breast cancer. Sci Rep. 2023; 13(1):1258. PMC: 9870904. DOI: 10.1038/s41598-022-25400-1. View

17.

Magri V, Marino L, Nicolazzo C, Gradilone A, De Renzi G, De Meo M . Prognostic Role of Circulating Tumor Cell Trajectories in Metastatic Colorectal Cancer. Cells. 2023; 12(8). PMC: 10136568. DOI: 10.3390/cells12081172. View

18.

Alix-Panabieres C, Pantel K . Liquid Biopsy: From Discovery to Clinical Application. Cancer Discov. 2021; 11(4):858-873. DOI: 10.1158/2159-8290.CD-20-1311. View

19.

Knipper S, Riethdorf S, Werner S, Tilki D, Graefen M, Pantel K . Possible Role of Circulating Tumour Cells for Prediction of Salvage Lymph Node Dissection Outcome in Patients with Early Prostate Cancer Recurrence. Eur Urol Open Sci. 2021; 34:55-58. PMC: 8579141. DOI: 10.1016/j.euros.2021.09.017. View

20.

Joosse S, Beyer B, Gasch C, Nastaly P, Kuske A, Isbarn H . Tumor-Associated Release of Prostatic Cells into the Blood after Transrectal Ultrasound-Guided Biopsy in Patients with Histologically Confirmed Prostate Cancer. Clin Chem. 2019; 66(1):161-168. DOI: 10.1373/clinchem.2019.310912. View